Stemedica Cell Technologies Inc., of San Diego, said its ischemic adult allogeneic mesenchymal stem cells were used successfully to treat the first patient in an ischemic stroke study. A total of 35 patients will be enrolled in the study, which is designed to determine tolerance and therapeutic outcomes for the intravenously delivered stem cells.